Terms: = Lymphoma AND CDKN2A, CDK4I, 1029, ENSG00000147889, P42771, p14, CMM2, ARF, TP16, p16, MTS1, p19, p16INK4a, INK4a, CDKN2, p16INK4, p14ARF, MLM, INK4
1312 results:
1. Efficacy and Nuances of Precision Molecular Engineering for Hodgkin's Disease to a Gene Therapeutic Approach.
Qadir MI; Ahmed B; Hussain N
Crit Rev Immunol; 2024; 44(5):41-50. PubMed ID: 38618727
[TBL] [Abstract] [Full Text] [Related]
2. Refining risk stratification in paediatric B-acute lymphoblastic leukaemia: Combining IKZF1
Liu HC; Huang YJ; Jaing TH; Wu KH; Chen SH; Wang SC; Yeh TC; Hsiao CC; Chang TK; Yen HJ; Huang FL; Lin PC; Hou JY; Sheen JM; Liao YM; Chang TY; Chen YC; Chiou SS; Yang CP; Pui CH; Liang DC; Shih LY
Br J Haematol; 2024 Apr; 204(4):1344-1353. PubMed ID: 38479427
[TBL] [Abstract] [Full Text] [Related]
3. Integrated analysis of transcriptome and genome variations in pediatric T cell acute lymphoblastic leukemia: data from north Indian tertiary care center.
Singh M; Sharma P; Bhatia P; Trehan A; Thakur R; Sreedharanunni S
BMC Cancer; 2024 Mar; 24(1):325. PubMed ID: 38459434
[TBL] [Abstract] [Full Text] [Related]
4. The mechanisms behind the dual role of long non-coding RNA (lncRNA) metastasis suppressor-1 in human tumors: Shedding light on the molecular mechanisms.
Abdullaev B; Alsaab HO; Hjazi A; Alkhafaji AT; Alawadi AH; Hamzah HF
Pathol Res Pract; 2024 Apr; 256():155189. PubMed ID: 38452581
[TBL] [Abstract] [Full Text] [Related]
5. MUC20 regulated by extrachromosomal circular DNA attenuates proteasome inhibitor resistance of multiple myeloma by modulating cuproptosis.
Wang X; Shi Y; Shi H; Liu X; Liao A; Liu Z; Orlowski RZ; Zhang R; Wang H
J Exp Clin Cancer Res; 2024 Mar; 43(1):68. PubMed ID: 38439082
[TBL] [Abstract] [Full Text] [Related]
6. Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLC.
Nakazawa M; Harada G; Ghanem P; Bubie A; Kiedrowski LA; Murray JC; Marrone KA; Scott SC; Houseknecht S; Falcon CJ; Evans P; Feliciano J; Hann CL; Ettinger DS; Smith KN; Anagnostou V; Forde PM; Brahmer JR; Levy B; Drilon A; Lam VK
Cancer Res Commun; 2024 Mar; 4(3):786-795. PubMed ID: 38407352
[TBL] [Abstract] [Full Text] [Related]
7. Dissecting the genome sequence of a clinical isolated Cunninghamella bertholletiae Z2 strain with rich cytochrome P450 enzymes (Article).
Zhou EM; Chen XA; Zhou MM; Xu LY; Wang D; Shen HP; Xu WQ
Infect Genet Evol; 2024 Jun; 120():105575. PubMed ID: 38403034
[TBL] [Abstract] [Full Text] [Related]
8. Tyrosine kinase inhibitor resistance in de novo BCR::ABL1-positive BCP-ALL beyond kinase domain mutations.
van Outersterp I; Boer JM; van de Ven C; Reichert CEJ; Boeree A; Kruisinga B; de Groot-Kruseman HA; Escherich G; Sijs-Szabo A; Rijneveld AW; den Boer ML
Blood Adv; 2024 Apr; 8(8):1835-1845. PubMed ID: 38386975
[TBL] [Abstract] [Full Text] [Related]
9. Combination of minimal residual disease on day 15 and copy number alterations results in BCR-ABL1-negative pediatric B-ALL: A powerful tool for prediction of induction failure.
Baghdadi H; Soleimani M; Zavvar M; Bahoush G; Poopak B
Cancer Genet; 2024 Apr; 282-283():27-34. PubMed ID: 38183785
[TBL] [Abstract] [Full Text] [Related]
10. Homozygous Loss of cdkn2 in Primary Cutaneous CD8(+) lymphoma NOS.
Robson A; Costa Rosa J; Semkova K; Bakr F; Cabecadas J
Am J Dermatopathol; 2024 Mar; 46(3):147-152. PubMed ID: 38175704
[TBL] [Abstract] [Full Text] [Related]
11. Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL.
Bastian L; Beder T; Barz MJ; Bendig S; Bartsch L; Walter W; Wolgast N; Brändl B; Rohrandt C; Hansen BT; Hartmann AM; Iben K; Das Gupta D; Denker M; Zimmermann J; Wittig M; Chitadze G; Neumann M; Schneller F; Fiedler W; Steffen B; Stelljes M; Faul C; Schwartz S; Müller FJ; Cario G; Harder L; Haferlach C; Pfeifer H; Gökbuget N; Brüggemann M; Baldus CD
Blood; 2024 Apr; 143(14):1391-1398. PubMed ID: 38153913
[TBL] [Abstract] [Full Text] [Related]
12. DNA Copy Number Alterations and Copy Neutral Loss of Heterozygosity in Adult Ph-Negative Acute B-Lymphoblastic Leukemia: Focus on the Genes Involved.
Risinskaya N; Gladysheva M; Abdulpatakhov A; Chabaeva Y; Surimova V; Aleshina O; Yushkova A; Dubova O; Kapranov N; Galtseva I; Kulikov S; Obukhova T; Sudarikov A; Parovichnikova E
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139431
[TBL] [Abstract] [Full Text] [Related]
13. Risk of malignancy in incidental oropharyngeal lesions exhibiting fluorodeoxyglucose uptake which proceed to tissue biopsy.
Key S; Chia C; Magarey M; Dixon B
ANZ J Surg; 2024 Feb; 94(1-2):122-127. PubMed ID: 38115646
[TBL] [Abstract] [Full Text] [Related]
14. miR-17-92 cluster-BTG2 axis regulates B-cell receptor signaling in mantle cell lymphoma.
Kawaji-Kanayama Y; Tsukamoto T; Nakano M; Tokuda Y; Nagata H; Mizuhara K; Katsuragawa-Taminishi Y; Isa R; Fujino T; Matsumura-Kimoto Y; Mizutani S; Shimura Y; Taniwaki M; Tashiro K; Kuroda J
Cancer Sci; 2024 Feb; 115(2):452-464. PubMed ID: 38050664
[TBL] [Abstract] [Full Text] [Related]
15. Cytogenetics in the management of mature T-cell and NK-cell neoplasms: Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH).
Gaillard JB; Chapiro E; Daudignon A; Nadal N; Penther D; Chauzeix J; Nguyen-Khac F; Veronese L; Lefebvre C
Curr Res Transl Med; 2023; 71(4):103428. PubMed ID: 38016421
[TBL] [Abstract] [Full Text] [Related]
16. The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib.
Sartori G; Tarantelli C; Spriano F; Gaudio E; Cascione L; Mascia M; Barreca M; Arribas AJ; Licenziato L; Golino G; Ferragamo A; Pileri S; Damia G; Zucca E; Stathis A; Politz O; Wengner AM; Bertoni F
Br J Haematol; 2024 Jan; 204(1):191-205. PubMed ID: 38011941
[TBL] [Abstract] [Full Text] [Related]
17. Differential expression of BCL11b and cdkn2a in CD30-positive peripheral T cell lymphoma: Retrospective study.
Wang Y; Zhang F; Gao N; Bu P; Cui W; Xi Y
Medicine (Baltimore); 2023 Nov; 102(46):e35531. PubMed ID: 37986346
[TBL] [Abstract] [Full Text] [Related]
18. Next-Generation Sequencing of Vitreoretinal lymphoma by Vitreous Liquid Biopsy: Diagnostic Potential and Genotype/Phenotype Correlation.
Kwak JJ; Lee KS; Lee J; Kim YJ; Choi EY; Byeon SH; Chang WS; Kim YR; Kim JS; Shin S; Lee ST; Kim SS; Lee CS
Invest Ophthalmol Vis Sci; 2023 Nov; 64(14):27. PubMed ID: 37975847
[TBL] [Abstract] [Full Text] [Related]
19. [Molecular diagnostics for vitreoretinal lymphoma].
Bonzheim I; Salmerón-Villalobos J; Süsskind D; Szurman P; Gekeler F; Spitzer MS; Salaverria I; Campo E; Coupland SE; Quintanilla-Martinez L; Fend F
Pathologie (Heidelb); 2023 Dec; 44(Suppl 3):150-154. PubMed ID: 37947807
[TBL] [Abstract] [Full Text] [Related]
20. Adolescent and young adult Hodgkin lymphoma patients at risk for subcutaneous fat gain during early cancer treatment: a brief report.
Wooten SV; Amini B; Roth M; Leung CH; Wang J; Hildebrandt MAT; Kleinerman E
Leuk Lymphoma; 2024 Jan; 65(1):62-68. PubMed ID: 37878765
[TBL] [Abstract] [Full Text] [Related]
[Next]
